Jasco Pharmaceuticals' Pipeline
Click on the program for additional information.
Pim kinases are an exciting class of serine/threonine protein kinases with a structurally unique ATP binding pocket incorporated in all three isoforms (Pim-1, Pim-2 and Pim-3). The Pims are key components of the JAK/STAT signaling pathway and regulate cancer cell survival providing an important set of therapeutic targets for the treatment of various hematological malignancies and various solid tumors. Jasco Pharmaceuticals has developed structurally novel, potent, small molecules that selectively inhibit each of the three Pim isoforms, as well as molecules that inhibit all three Pims simultaneously. Jasco’s lead series has been identified to significantly inhibit cell proliferation in several cancer cell lines, and has shown good translation to the corresponding efficacy models in mice.
Casein kinase I is a class of serine/threonine protein kinases that includes seven isomers (alpha, beta 1, gamma 1, gamma 2, gamma 3, delta, and epsilon). This family of kinases is involved in the regulation of signal transduction with important roles in the Wnt and Hedgehog signaling pathways. Jasco Pharmaceuticals has developed structurally novel, potent, and selective small molecule inhibitors of certain CK1 isoforms including CK1α, CK1γ1, CK1γ2, and CK1γ3. The inhibitors have also been identified to significantly reduce cell proliferation in several cancer cell lines.
Casein kinase II is a serine/threonine protein kinase that is involved in many cellular functions including apoptosis, angiogenesis, singnal transduction, and inflammation, which makes it an interesting therapeutic target for the treatment of varous cancers. Jasco Pharmaceuticals has developed structurally novel, potent, and selective small molecule inhibitors of CK2α that have been identified to significantly reduce cell proliferation in several cancer cell lines.